Cargando…

Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression

Triple-negative breast cancer (TNBC) is often treated with anthracyclines (e.g., epirubicin or doxorubicin), but very little is known about anthracycline resistance, especially epirubicin resistance in TNBC. To identify novel long noncoding RNAs (lncRNAs) involved in epirubicin resistance in TNBC, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fengliang, Yang, Sujin, Lv, Mingming, Chen, Fei, Yin, Hong, Gao, Sheng, Tang, Jinhai, Yu, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970185/ https://www.ncbi.nlm.nih.gov/pubmed/33747911 http://dx.doi.org/10.3389/fonc.2021.592215

Ejemplares similares

Long Noncoding RNA MIR210HG Promotes the Warburg Effect and Tumor Growth by Enhancing HIF-1α Translation in Triple-Negative Breast Cancer
por: Du, Ye, et al.
Publicado: (2020)

Roles of long noncoding RNA in triple‐negative breast cancer
por: Das, Plabon Kumar, et al.
Publicado: (2023)

The long non‐coding RNA landscape in triple‐negative breast cancer
por: Zhang, Wenwen, et al.
Publicado: (2020)

High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer
por: Han, Tao, et al.
Publicado: (2015)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

MIIP functions as a novel ligand for ITGB3 to inhibit angiogenesis and tumorigenesis of triple-negative breast cancer
por: Gao, Yujing, et al.
Publicado: (2022)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

Prognostic Factor Analysis and Model Construction of Triple-Negative Metaplastic Breast Carcinoma After Surgery
por: Zhu, Keying, et al.
Publicado: (2022)

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
por: Li, Junjie, et al.
Publicado: (2020)

Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
por: Kota, Karthik, et al.
Publicado: (2017)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

Editorial: Triple-negative breast cancer: Heterogeneity, tumor microenvironment and targeted therapy
por: Deng, Xiyun, et al.
Publicado: (2022)

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer
por: Gong, Yajie, et al.
Publicado: (2020)

ITGB1-mediated molecular landscape and cuproptosis phenotype induced the worse prognosis in diffuse gastric cancer
por: Zhu, Xingyu, et al.
Publicado: (2023)

Unraveling Heterogeneity of Tumor Cells and Microenvironment and Its Clinical Implications for Triple Negative Breast Cancer
por: Jiang, Ke, et al.
Publicado: (2021)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Construction and Identification of New Molecular Markers of Triple-Negative Breast Cancer Stem Cells
por: Liu, Tingting, et al.
Publicado: (2021)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
por: Li, Fu, et al.
Publicado: (2023)

The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer
por: Huang, Jianbo, et al.
Publicado: (2017)

Inhibition of 6-Phosphogluconate Dehydrogenase Reverses Epirubicin Resistance Through Metabolic Reprograming in Triple-Negative Breast Cancer Cells
por: Xu, Jiali, et al.
Publicado: (2023)

A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers
por: Liu, Man, et al.
Publicado: (2017)

Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer
por: Wu, Song, et al.
Publicado: (2022)

Long noncoding RNA HULC contributes to paclitaxel resistance in ovarian cancer via miR-137/ITGB8 axis
por: Huang, Bo, et al.
Publicado: (2021)

Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer
por: Cai, Shuang-Long, et al.
Publicado: (2023)

LncRNA TCF7 Promotes Epithelial Ovarian Cancer Viability, Mobility and Stemness via Regulating ITGB8
por: Su, Changlei, et al.
Publicado: (2021)

ASMT Regulates Tumor Metastasis Through the Circadian Clock System in Triple-Negative Breast Cancer
por: Xie, FenFen, et al.
Publicado: (2020)

Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer
por: Iorio, Egidio, et al.
Publicado: (2016)

Hyperoxygenation as a Therapeutic Supplement for Treatment of Triple Negative Breast Cancer
por: Mast, Jesse M., et al.
Publicado: (2018)

Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
por: Navarrete-Bernal, María G. C., et al.
Publicado: (2020)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer
por: Cui, Xiang, et al.
Publicado: (2020)

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
por: Qiu, Xia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mqfnpd8327fduu7m9d89edrajq